methods and compositions for infusion of selected populations of transient allogeneic lymphocyte grafting for cancer treatment

摘要

abstract of the invention the invention provides methods and compositions for administration of allogeneic lymphocytes as an exogenous source of cd4 + t cell help for endogenous, tumor-reactive cd8 + t cells. depletion of cd8 + t cells from the donor lymphocyte infusion decreases the risk of sustained engraftment and graft-versus-host disease. removal of regulatory t cells from the infused population may augment the ability of non-regulatory t cells to provide help for endogenous effectors of anti-tumor immunity. allogeneic t cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature t cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector cells derive from the host. ********************************* Abstract of the Summary Patent Summary: "Methods and compositions for infusion of selected populations of transient allogeneic lymphocyte grafting for cancer treatment ". The invention provides methods and compositions for administering allogeneic lymphocytes as an exogenous source of cd4 + t cell support to endogenous tumor reactive cd8 + t cells. cd8 + t cell depletion from donor lymphocyte infusion reduces the risk of graft versus host disease and sustained grafting. Removal of regulatory T cells from the infused population may increase the ability of non-regulatory T cells to provide support for endogenous effectors of anti-tumor immunity. Allogeneic T-cell therapy is typically given in the context of allogeneic stem cell transplantation, where the patient receives highly immunosuppressive conditioning succeeded by an infusion of a stem cell graft containing unselected mature T-cell populations. In the treatment described herein, the graft is modified to minimize the possibility of sustained donor cell grafting, and anti-tumor effector cells are derived from the host. 23020494v1 1/1 23020494v1